University of Bordeaux

Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board

Retrieved on: 
Thursday, August 10, 2023
SAB, Electroporation, Brain, University, Neoplasm, ZEUS robotic surgical system, Spine, Cryotherapy, Research, Sorbonne University, Doctor of Philosophy, Pain, MRI, Interventional radiology, MD, Faculty, Neuro, Robotics, University of Bordeaux, Medical imaging, Radiology

Professor Cornelis is an interventional radiologist who specializes in neuro interventions and image-guided minimally invasive therapies that allow for pain palliation and tumor control in the bones and spine.

Key Points: 
  • Professor Cornelis is an interventional radiologist who specializes in neuro interventions and image-guided minimally invasive therapies that allow for pain palliation and tumor control in the bones and spine.
  • Professor Cornelis received his MD in 2003 and completed his radiology training and his fellowship in 2008 and 2010, respectively, at the University of Bordeaux in France.
  • “The support and endorsement of a global leader such as Professor Cornelis is a vote of confidence and a great honor for the company.
  • Professor Cornelis joins a team of global leaders in their fields that are already serving as members of our SAB,” said Dr. Eyal Morag, Chief Medical Officer of Microbot Medical.

European Extracellular Vesicles & Nanoparticle-based Therapeutics Conference 2023: Explore Cutting-Edge Innovations and Therapeutic Opportunities (Rotterdam, Netherlands - November 13-14, 2023) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 25, 2023
Other Health, Research, Pharmaceutical, Medical Devices, Technology, Hospitals, Science, Surgery, Nanotechnology, Biotechnology, Other Science, Health, EV, University, Exhibition, Engineering, Associate professor, University Medical Center, Head, Therapy, Eurostar, University of Bordeaux, Medical biology, Teaching hospital, Seminal vesicles, A*STAR, Transfusion medicine, Faculty, Nanoparticle, International Society for Extracellular Vesicles, Vaccine, Conference, Medical device, Management, Pharmaceutical industry, Hospital, Nanomedicine

The "Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023" conference has been added to ResearchAndMarkets.com's offering.
  • Welcome to the Extracellular Vesicles (EV) & Nanoparticle-based Therapeutics Europe 2023 Conference to be held 13-14 November 2023 at the Hilton Rotterdam, The Netherlands.
  • At this conference we bring together speaking faculty who represent academic thought leaders as well as leading industry participants translating technologies into commercial offerings and innovations in the field.
  • The conference features extensive networking opportunities and is held 7-minutes walk from Rotterdam Centraal with fast and very easy access to Amsterdam-Schiphol with worldwide connections as well as the Eurostar to London plus fast-trains to Antwerp, Brussels and Paris.

European Extracellular Vesicles & Nanoparticle-based Therapeutics Conference 2023: Advancing Therapeutics - Industry Giants and Academic Experts Converge (Rotterdam, Netherlands, November 13-14, 2023)

Retrieved on: 
Monday, July 24, 2023
EV, University, Exhibition, Engineering, Associate professor, University Medical Center, Head, Therapy, Eurostar, University of Bordeaux, Medical biology, Teaching hospital, Seminal vesicles, A*STAR, Transfusion medicine, Faculty, Nanoparticle, Research, International Society for Extracellular Vesicles, Vaccine, Conference, Management, Pharmaceutical industry, Hospital, Nanomedicine

DUBLIN, July 24, 2023 /PRNewswire/ -- The "Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 24, 2023 /PRNewswire/ -- The "Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023" conference has been added to ResearchAndMarkets.com's offering.
  • Welcome to the Extracellular Vesicles (EV) & Nanoparticle-based Therapeutics Europe 2023 Conference to be held 13-14 November 2023 at the Hilton Rotterdam, The Netherlands.
  • At this conference we bring together speaking faculty who represent academic thought leaders as well as leading industry participants translating technologies into commercial offerings and innovations in the field.
  • This conference features scientific presentations, industry technology spotlight presentations, posters as well as a co-located exhibition, and the conference features companies in this field developing technologies, products and services as well as moving (clinical) candidates forward into the clinical trials regimen.

BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer

Retrieved on: 
Wednesday, July 12, 2023
GSK, Brainstorm, Therapy, Internal medicine, Advisory Committee, Research, Medicine, Science, American Board of Commissioners for Foreign Missions, MD, Psychiatry, PDUFA, Neurology, Rare, FDA, Boston Medical Center, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, University of Bordeaux, ALS, Food, Pharmaceutical industry

NEW YORK, July 12, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Bob Dagher, MD, as Executive Vice President and Chief Development Officer effective July 17, 2023. Dr. Dagher will serve on BrainStorm's executive leadership team reporting to Stacy Lindborg, Ph.D., co-CEO of BrainStorm.  He will be responsible for the portfolio strategy and advancement of clinical development plans towards regulatory approval, including the expansion of NurOwn into new diseases and the translation of pre-clinical research into first-in-human trials. 

Key Points: 
  • NEW YORK, July 12, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Bob Dagher, MD, as Executive Vice President and Chief Development Officer effective July 17, 2023.
  • Dr. Dagher will serve on BrainStorm's executive leadership team reporting to Stacy Lindborg, Ph.D., co-CEO of BrainStorm.
  • Dr. Dagher joins BrainStorm from Enveric Biosciences where, as Chief Medical Officer, he was responsible for defining the portfolio strategy and advancement of development plans toward regulatory approvals.
  • I believe Brainstorm has an innovative and versatile, industry-leading stem cell technology platform, which can rapidly advance autologous targeted therapeutics from bench to clinical development and eventual commercialization.

EQS-News: Carbios accelerates its enzyme optimization with screening capabilities for millions of enzymes in a day

Retrieved on: 
Tuesday, April 18, 2023
Carbios, Acceleration, Plastic, Partnership, University, Nature, INSA, OMICS Publishing Group, Enzyme, Polymer, PET, TBI, Clermont-Ferrand, CNRS, R, Robotics, Textile, University of Bordeaux, Fine chemical, Microfluidics

This cutting-edge technology enables the screening of millions of enzymes in just one day, speeding up the process to optimize enzymes breaking down PET.

Key Points: 
  • This cutting-edge technology enables the screening of millions of enzymes in just one day, speeding up the process to optimize enzymes breaking down PET.
  • "Since having applied microfluidics to our screening process more than a year ago, we have analyzed millions of enzymes, which would have taken years beforehand," explains Prof. Alain Marty, Chief Scientific Officer at Carbios.
  • These droplets move through analysis units the size of a microchip allowing ultra-high throughput screening of 150 enzymes per second.
  • Alexandra Tauzin, Researcher in Enzyme Engineering and Microfluidics, and Alexandre Gilles, Engineer specialized in robotics, work in partnership with the Paul Pascal Research Center.

Zai Lab Appoints Michel Vounatsos To Its Board of Directors

Retrieved on: 
Monday, January 9, 2023
MSD, Customer satisfaction, PerkinElmer, Electrophysiology, University, Tsinghua University School of Economics and Management, Pharmacy, HKEX, Novartis, HEC Paris, University of Bordeaux, Growth, Patient, Audit committee, MBA, Merck & Co., Supervisory board, Management, Merck, Biogen, Medicine

SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023.

Key Points: 
  • SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023.
  • Mr. Vounatsos brings to the Board extensive global leadership and management experience in the biopharmaceutical industry, including more than 25 years of service at leading companies.
  • “We are delighted to welcome Michel Vounatsos to the Zai Lab Board of Directors,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab.
  • In particular, his deep development and commercial experience in neuroscience will significantly benefit the Company as we continue to enhance our expertise in this key therapeutic area.”
    “I’m thrilled to be joining the Zai Lab Board of Directors at such a pivotal time in the company’s growth,” said Michel Vounatsos.

Adagio Medical Announces Publication of Cryocure-2 Data Reporting 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Discusses Current Status of iCLAS™ Cryoablation System

Retrieved on: 
Thursday, July 28, 2022
Atrial flutter, Amsterdam, University, Freedom, Population, Doctor of Philosophy, Arrhythmia, VT, Temperature, Ventricular tachycardia, NCT, CEO, Heart Rhythm Society, Catheter ablation, Safety, Associate Director of National Intelligence and Chief Information Officer, Journal, Atrial fibrillation, EP, Technology, University of Bordeaux, FDA, ICLA, MD, Patient, RF, JACC, Lists of Palestinian rocket attacks on Israel, AF, Manuscript, Medical device, Adagio

The one-year freedom from AF after a single procedure was 82%, with 1.5% procedural complications rate when using ULTC technology.

Key Points: 
  • The one-year freedom from AF after a single procedure was 82%, with 1.5% procedural complications rate when using ULTC technology.
  • "Today's publication reaffirms the interest of the EP community in ULTC technology for the treatment of AF and other cardiac arrhythmias.
  • The Cryocure-PMCF (NCT # 05416086) open-label post-market clinical follow-up evaluation of iCLAS system isenrolling both paroxysmal and persistent AF patients at several European centers.
  • The safety and effectiveness of the iCLAS system for the treatment of persistent AF is a subject of FDA IDE trial in the US (NCT # 04061603).

Adagio Medical Announces Publication of Cryocure-2 Data Reporting 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Discusses Current Status of iCLAS™ Cryoablation System

Retrieved on: 
Thursday, July 28, 2022
Atrial flutter, Amsterdam, University, Freedom, Population, Doctor of Philosophy, Arrhythmia, VT, Temperature, Ventricular tachycardia, NCT, CEO, Heart Rhythm Society, Catheter ablation, Safety, Associate Director of National Intelligence and Chief Information Officer, Journal, Atrial fibrillation, EP, Technology, University of Bordeaux, FDA, ICLA, MD, Patient, RF, JACC, Lists of Palestinian rocket attacks on Israel, AF, Manuscript, Medical device, Adagio

The one-year freedom from AF after a single procedure was 82%, with 1.5% procedural complications rate when using ULTC technology.

Key Points: 
  • The one-year freedom from AF after a single procedure was 82%, with 1.5% procedural complications rate when using ULTC technology.
  • "Today's publication reaffirms the interest of the EP community in ULTC technology for the treatment of AF and other cardiac arrhythmias.
  • The Cryocure-PMCF (NCT # 05416086) open-label post-market clinical follow-up evaluation of iCLAS system isenrolling both paroxysmal and persistent AF patients at several European centers.
  • The safety and effectiveness of the iCLAS system for the treatment of persistent AF is a subject of FDA IDE trial in the US (NCT # 04061603).

Colorado State University Global Names Dr. Angela Hernquist Vice President of Student and Faculty Operations

Retrieved on: 
Tuesday, June 21, 2022
Aurora, Doctor of Philosophy, University of Colorado Denver School of Public Affairs, CSU, Education, Business administration, Student affairs, Achievement, Reno 1868 FC, Research, Parent, Sherwin-Williams, Student, Higher education, Interim, University, University system, Counselor, London School of Business and Finance, Leadership, Associate, London, Colorado State University–Global Campus, Assistant, GLOBE, University of Bordeaux, Management, Tutoring, Medicine, Faculty, Economics

Aurora, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- Colorado State University Global (CSU Global) President Pamela Toney has named Dr. Angela Hernquist as Vice President of Student and Faculty Operations.

Key Points: 
  • Aurora, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- Colorado State University Global (CSU Global) President Pamela Toney has named Dr. Angela Hernquist as Vice President of Student and Faculty Operations.
  • Dr. Hernquist joined CSU Global in 2014 as the Associate Director of Faculty Operations and has since led numerous strategic initiatives across various departments.
  • At the university, she has also served as Director of Faculty and Academic Affairs, Assistant Vice President of Student Affairs, Interim Assistant Provost, and Interim Provost.
  • Colorado State University Global (CSU Global) offers career-relevant bachelors and masters degree programs for working adults and nontraditional learners.

Dufry Publishes Invitation to its Ordinary General Meeting on May 17, 2022

Retrieved on: 
Thursday, April 14, 2022
2015 Swiss Federal Council election, Board, Audit committee, COVID-19, Economics, Efficiency, Federal Council, Board of directors, Company, University of Bordeaux, Letter, Supervisory board, Coronavirus, Independent, Swiss, CEST, University, Institute, Holding company, Management, Dufry, Edei, Director

Dufry today published the invitation to the Ordinary General Meeting 2022.

Key Points: 
  • Dufry today published the invitation to the Ordinary General Meeting 2022.
  • The shareholders of Dufry AG may exercise their rights at the Ordinary General Meeting exclusively through the Independent Voting Rights Representative.
  • The Ordinary General Meeting invitation and agenda as well as the Letter of Dufry's Chairman to Shareholders can be accessed here: 2022 Ordinary General Meeting
    The Board of Directors proposes the re-election of Juan Carlos Torres Carretero as Chairman of the Board of Directors.
  • The Board of Directors is further proposing to the Ordinary General Meeting the re-election of all other Board members.